After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva ...

Novo Nordisk's parent company Novo Holdings has led a $100 million third-round financing for Swiss biotech Asceneuron, which ...

Clinical trials are strictly regulated to ensure patient safety, but the current framework in the UK is stifling early-phase ...

A digital test that will help to provide a faster diagnosis for people with attention deficit hyperactivity disorder (ADHD) ...

An experimental gene therapy developed by Lexeo Therapeutics has shown early promise in treating one of the most serious ...

Vision loss associated with diabetes is one of the more prevalent and growing healthcare burdens in the Western world. In today’s podcast, web editor Nicole Raleigh welcomes Dr Catherine Beech, CEO of ...

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) ...

An observational study carried out by researchers at Oxford University published in The Lancet journal eClinical Medicine has ...

Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court, after ...

Germany’s recent adoption of the Medical Research Act (MFG) means that, for the first time, it could become possible for ...

The spate of delisting decisions follows a slump in new issues on the AIM during 2023 – hitting lows not seen in more than 20 ...

A snap analysis of over 100 posts on social media from 90 HCPs relating to cancer vaccinations found on the surface the same ...